Liquid Biopsy Market Projected to Reach USD 10,938.6 Million by 2033 at a 21.7% of CAGR

The global liquid biopsy market is poised for significant growth, with estimates suggesting a revenue of USD 1,538.3 million in 2023 and projected to reach USD 10,938.6 million by 2033. This growth trajectory reflects a robust compound annual growth rate (CAGR) of 21.7% during the forecast period, driven by increasing adoption of non-invasive diagnostic techniques and advancements in cancer screening technologies.

Liquid biopsy involves the analysis of biomarkers, such as circulating tumor cells (CTCs) and cell-free DNA (cfDNA), extracted from blood or other bodily fluids to detect and monitor various diseases, primarily cancer. The market’s expansion is propelled by its ability to provide early and accurate diagnosis, monitor treatment response, and facilitate personalized medicine approaches.

The market for liquid biopsies is growing at a rapid pace due to several factors, including the rising incidence of cancer, the development of genetic technologies, and the rising need for less invasive diagnostic techniques. Liquid biopsies have the potential to change the field of disease identification and management, and this is a realization that both patients and healthcare providers are beginning to see.

Get your PDF Sample Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-1396

Liquid biopsies have become more common in recent years due to the desire for more personalized treatment options. Since liquid biopsy is widely available and reasonably priced in many labs, particularly in developing countries, its use is growing in popularity. For instance, several labs offer liquid biopsy tests.

“Key players are bringing cost reductions in liquid biopsy tests and partnering with local product distributors to strengthen their network base in target markets. Currently, a trend toward emerging economies has been spotted, as cancer cases are particularly on the rise, and a large population base provides significant opportunities in these markets,” says an FMI analyst.

Key Takeaways from the Liquid Biopsy Market Report

• The North America liquid biopsy market is expected to account for a leading share of 50.84%. The United States is predicted to account for 43.8%, enjoying a dominant share in the global and regional markets.
• The Europe market is anticipated to acquire a market share of 19.6% in 2023. Germany holds a prominent share in the region. In 2023, the country is predicted to amass a total of 6.6% share in the global market.
• In Europe, the United Kingdom is predicted to expand at a robust CAGR of 26.4% through 2033.
• In Asia Pacific, China and India display a remarkable percentage of growth, i.e., 29.7% and 24.4%, respectively, through 2033.
• CTC (Circulating Tumor Cells) is projected to obtain a significant market share of 56.9% by biomarker type in 2023.
• By sample type, blood sample type holds prominence in the liquid biopsy market.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-1396

Key Developments by Liquid Biopsy Market Players

• QIAGEN N.V. (the Netherlands), in May 2022, introduced a therascreen EGFR Plus RGQ PCR Kit, which is a new in vitro diagnostic test for the analysis of sensitive EGFR mutation.
• Guardant Health, Inc., in June 2021, introduced Guardant360 Response test that finds variations in circulating tumor DNA (ctDNA) levels.
• Hoffmann-La Roche Ltd. (Switzerland), in October 2020, gained United States FDA approval for the extended claims for cobas EGFR Mutation Test v2 to be deployed as a companion diagnostic for an extensive range of therapies to manage non-small cell lung cancer (NSCLC).
• Biocept, Inc., in March 2020, agreed with a California-based Independent Physician Association (IPA) to offer its Target Selector liquid assay services to patients and physicians in the network.

Key Companies Profiled:

• BIOCEPT, INC.
• Qiagen N.V.
• Trovagene, Inc
• Janssen Global Services, LLC
• MDxHealth SA
• Natera, Inc
• F. Hoffmann-La Roche Ltd
• Silicon Biosystems
• Pathway Genomics Corporation
• Sysmex Corporation
• Others

Key Segments Profiled in the Liquid Biopsy Industry Survey:

By Biomarker Type:

• CTCs (Circulating Tumour Cells)
• ctNA (Circulating tumor Nucleic Acids)
• Exosomes

By Sample Type:

• Blood Liquid Biopsy
• Urine Liquid Biopsy
• Other (Plasma, Saliva, CSF) Liquid Biopsy

By Application Type:

• Liquid Biopsy for Lung Cancer
• Liquid Biopsy for Gastrointestinal Cancer
• Liquid Biopsy for Prostate Cancer
• Liquid Biopsy for Breast Cancer
• Liquid Biopsy for Colorectal Cancer
• Liquid Biopsy for Leukemia

By Region:

• North America
• Latin America
• Western Europe
• Eastern Europe
• Asia Pacific Excluding Japan
• Japan
• Middle East and Africa

Obtain In-Depth Market Insights: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/1396

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube